Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Medical Equipment Industry Analysis

UpdatedJul 10, 2026
DataAggregated Company Financials
Companies50
  • 7D0.02%
  • 3M4.9%
  • 1Y-10.0%
  • YTD-1.9%

Over the last 7 days, the Medical Equipment industry has remained flat, although notably Xvivo Perfusion gained 8.7%. As for the longer term, the industry has declined 11% in the last year. Earnings are forecast to grow by 22% annually.

Industry Valuation and Performance

Has the Swedish Medical Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 10 Jul 2026SEK 143.0bSEK 73.3bSEK 1.5b30.9x96.3x2x
Sun, 07 Jun 2026SEK 138.6bSEK 73.2bSEK 1.5b32.4x90.1x1.9x
Tue, 05 May 2026SEK 132.0bSEK 73.6bSEK 2.0b27.4x66.9x1.8x
Thu, 02 Apr 2026SEK 134.7bSEK 74.6bSEK 1.7b24.2x77.7x1.8x
Sat, 28 Feb 2026SEK 145.3bSEK 74.9bSEK 2.1b27.7x69.8x1.9x
Mon, 26 Jan 2026SEK 144.4bSEK 77.4bSEK 1.9b37.5x75.1x1.9x
Wed, 24 Dec 2025SEK 175.9bSEK 94.0bSEK 2.4b45.4x72.4x1.9x
Fri, 21 Nov 2025SEK 172.0bSEK 94.3bSEK 2.4b44.5x71.7x1.8x
Sun, 19 Oct 2025SEK 177.6bSEK 93.3bSEK 1.4b46.6x127.4x1.9x
Tue, 16 Sep 2025SEK 186.7bSEK 93.3bSEK 1.4b50x133.7x2x
Thu, 14 Aug 2025SEK 189.2bSEK 93.5bSEK 1.4b44.1x130.7x2x
Sat, 12 Jul 2025SEK 199.8bSEK 93.4bSEK 1.5b43x132.3x2.1x
Mon, 09 Jun 2025SEK 193.5bSEK 93.4bSEK 1.5b35.5x130.2x2.1x
Wed, 07 May 2025SEK 174.2bSEK 92.6bSEK 2.4b29.6x73.7x1.9x
Fri, 04 Apr 2025SEK 177.0bSEK 91.4bSEK 2.9b30.6x61.9x1.9x
Sun, 02 Mar 2025SEK 164.7bSEK 76.6bSEK 2.1b29.9x79.3x2.2x
Tue, 28 Jan 2025SEK 162.4bSEK 74.7bSEK 1.8b32.5x89x2.2x
Thu, 26 Dec 2024SEK 156.1bSEK 74.7bSEK 1.8b28.8x85.6x2.1x
Sat, 23 Nov 2024SEK 153.5bSEK 75.1bSEK 2.0b27.1x77.1x2x
Mon, 21 Oct 2024SEK 170.7bSEK 74.8bSEK 2.2b32.1x77.1x2.3x
Wed, 18 Sep 2024SEK 180.9bSEK 74.5bSEK 3.1b25.5x58.1x2.4x
Fri, 16 Aug 2024SEK 173.6bSEK 74.4bSEK 3.3b30.4x53.2x2.3x
Sun, 14 Jul 2024SEK 167.9bSEK 73.1bSEK 2.7b31.2x63.1x2.3x
Tue, 11 Jun 2024SEK 162.4bSEK 72.8bSEK 2.6b30.8x61.6x2.2x
Thu, 09 May 2024SEK 173.8bSEK 73.1bSEK 2.7b32.6x63.2x2.4x
Sat, 06 Apr 2024SEK 165.7bSEK 72.3bSEK 2.4b32.3x68.5x2.3x
Mon, 04 Mar 2024SEK 162.7bSEK 72.2bSEK 2.4b33.8x67.5x2.3x
Wed, 31 Jan 2024SEK 174.4bSEK 71.7bSEK 1.7b45.6x103.1x2.4x
Fri, 29 Dec 2023SEK 174.0bSEK 71.3bSEK 1.5b41.4x113.4x2.4x
Sun, 26 Nov 2023SEK 165.6bSEK 70.0bSEK 1.3b35.7x130.4x2.4x
Tue, 24 Oct 2023SEK 141.6bSEK 69.7bSEK 1.2b26.1x116.8x2x
Thu, 21 Sep 2023SEK 152.0bSEK 68.8bSEK 1.1b30.2x139.9x2.2x
Sat, 19 Aug 2023SEK 154.3bSEK 68.2bSEK 836.7m30.4x184.4x2.3x
Mon, 17 Jul 2023SEK 157.3bSEK 67.5bSEK 735.2m33.5x213.9x2.3x
Price to Earnings Ratio

213.9x


Total Market Cap: SEK 157.3bTotal Earnings: SEK 735.2mTotal Revenue: SEK 67.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Medical Equipment Industry Price to Earnings3Y Average 92.4x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Medical Equipment industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 92.4x.
  • The industry is trading close to its 3-year average PS ratio of 2.1x.
Past Earnings Growth
  • The earnings for companies in the Medical Equipment industry have grown 2.3% per year over the last three years.
  • Revenues for these companies have grown 2.9% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare industry?

SE Market-0.65%
Healthcare-1.98%
Medical Equipment0.016%
Medical Supplies3.42%
Medical Equipment-0.72%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry which is trading above its 3-year average PE ratio of 79.4x.
    • Analysts are expecting annual earnings growth of 18.7%, which is higher than its past year's earnings decline of 11.9% per year.
  • Investors are most pessimistic about the Medical Supplies industry, although it looks like investor sentiment has improved given that it's trading above its 3-year average.
Forecasted Growth
  • Analysts are most optimistic on the Medical Supplies industry, expecting annual earnings growth of 35% over the next 5 years.
  • This is better than its past earnings growth rate of 22% per year.
  • In contrast, the Medical Equipment industry is expected to see its earnings grow by 19% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
XVIVO Xvivo PerfusionSEK 283.808.7%
+SEK 718.2m		-5.1%PE121x
IMP A SDB ImplanticaSEK 64.402.1%
+SEK 368.3m		17.5%PS756.1x
VIMIAN Vimian GroupSEK 30.400.8%
+SEK 132.3m		-28.9%PE39.6x
STIL StilleSEK 260.002.0%
+SEK 44.9m		13.5%PE37.7x
ORT B OrtomaSEK 9.478.4%
+SEK 34.2m		-31.1%PS10.4x

Latest News

CEVI
SEK 134.80
CellaVision
7D
-5.6%
1Y
-28.8%
Narrative Update • Jul 07

CEVI: New Leadership And Higher Margins Will Support Future Upside

Analysts have lowered their CellaVision price target from SEK211 to SEK180, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E multiples. What’s in the News for CellaVision CellaVision appointed Steve Ferguson as Chief Executive Officer, effective June 5, 2026.
EKTA B
SEK 50.85
Elekta
7D
-1.6%
1Y
3.2%
MCLR
SEK 2.88
Medclair
7D
11.6%
1Y
37.1%
OSSD
SEK 3.95
OssDsign
7D
-3.8%
1Y
-72.8%
Narrative Update • Jul 02

OSSD: Higher Margin Outlook And Lower P/E Will Support Future Re Rating

Analysts have adjusted their price target on OssDsign to SEK 6.40 from SEK 12.75, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple. What’s in the News for OssDsign OssDsign issued earnings guidance for the first quarter of 2026, indicating an expected loss before interest and taxes in the range of SEK 12.0 million to SEK 14.0 million, according to company guidance.
VIMIAN
SEK 30.40
Vimian Group
7D
0.8%
1Y
-28.9%
Narrative Update • Jun 30

VIMIAN: Lower Margin Outlook Will Limit Future Share Price Upside

Analysts have lifted their SEK fair value estimate for Vimian Group from about SEK 24.91 to roughly SEK 26.50. They cited updated assumptions for revenue growth, profit margins and a higher future P/E multiple as key drivers behind the change in price target.
BACTI B
SEK 16.50
Bactiguard Holding
7D
5.4%
1Y
-42.1%
Narrative Update • Jun 26

BACTI B: Renewed BD Alliance Will Drive Future Upside Potential

The analyst price target for Bactiguard Holding has been revised from SEK 38.75 to SEK 21.00, with analysts citing updated assumptions on profit margins, revenue growth and future P/E as the key factors behind this change. What’s in the News for Bactiguard Holding Bactiguard Holding AB proposed amendments to its articles of association, including the introduction of redeemable and convertible Class C shares alongside existing Class A and Class B shares, with detailed changes to §§ 6, 7 and 14 to govern voting rights, dividend entitlements, preemption rights, redemption and conversion processes.
GETI B
SEK 203.30
Getinge
7D
-0.7%
1Y
5.3%
Narrative Update • Jun 23

GETI B: Higher Dividend And Launch Of New EVH Platform Will Support Confidence

Analysts have maintained their SEK 270 price target for Getinge, citing updated assumptions for slightly lower discount rates, modestly higher revenue growth and profit margins, and supportive Street research, including an upgrade to Buy with a SEK 260 target. Together, these factors help underpin the current valuation view.
SUS
SEK 30.70
Surgical Science Sweden
7D
-6.8%
1Y
-79.8%
Narrative Update • Jun 23

SUS: Organic Expansion Will Support Sector Leadership As Profitability Assumptions Are Refined

Analysts have revised their price target for Surgical Science Sweden to SEK59.80 from SEK57.60. This reflects updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E expectations.
ORT B
SEK 9.47
Ortoma
7D
8.4%
1Y
-31.1%
SEDANA
SEK 8.95
Sedana Medical
7D
3.2%
1Y
-23.1%
Narrative Update • Jun 17

SEDANA: Early Access Milestone And 2026 NDA Filing Will Support Upside

Analysts have kept their SEK fair value estimate for Sedana Medical unchanged at SEK 18.0. They cite only small tweaks to the discount rate, long term revenue growth, profit margin, and future P/E assumptions. What’s in the News for Sedana Medical No recent Sedana Medical specific news items were identified in the provided primary news sources.
IMP A SDB
SEK 64.40
Implantica
7D
2.1%
1Y
17.5%
Analysis Article • Jun 16

Companies Like Implantica (STO:IMP A SDB) Can Afford To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
XVIVO
SEK 283.80
Xvivo Perfusion
7D
8.7%
1Y
-5.1%
Narrative Update • Jun 15

XVIVO: Strong Heart Trial Outcomes Will Drive Long Term Share Upside

Analysts have maintained their SEK 320.00 price target on Xvivo Perfusion, making small adjustments to assumptions for the discount rate, revenue growth, profit margin and future P/E that support an unchanged view on valuation. What's in the News XVIVO reported late breaking preliminary data from the PRESERVE Trial (NCT05881278) using the XVIVO Heart Assist Transport for hypothermic oxygenated perfusion, with the study meeting its pre specified primary endpoints in extended criteria donor hearts.
ARJO B
SEK 25.84
Arjo
7D
-2.4%
1Y
-25.2%
Narrative Update • Jun 15

ARJO B: Future Upside Will Rely On Stable Margins And Required Yield

Analysts are keeping their SEK price target for Arjo steady at SEK27.0, citing relatively unchanged fair value views, along with slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News No recent company specific news, periodical coverage, or key developments for Arjo were provided in the available sources.
STIL
SEK 260.00
Stille
7D
2.0%
1Y
13.5%
EPIS B
SEK 0.064
Episurf Medical
7D
-24.9%
1Y
5.8%
HEART
SEK 19.75
Scandinavian Real Heart
7D
-9.8%
1Y
49.1%